• FDA cleared an expanded US label for Pfizer’s hemophilia drug HYMPAVZI to cover patients ages 6+ with hemophilia A or B.
• Decision adds use in ages 6-11 with or without inhibitors; extends coverage to ages 12+ with inhibitors.
• Approval was backed by Phase 3 BASIS data, showing a 93% drop in treated annualized bleeding rate versus on-demand bypassing agents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260608815972) on June 08, 2026, and is solely responsible for the information contained therein.